bluebird bio, Inc.
NKG2D DARIC RECEPTORS
Last updated:
Abstract:
The present disclosure provides improved compositions for adoptive T cell therapies targeting NKG2D ligands for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.
Status:
Application
Type:
Utility
Filling date:
14 Dec 2018
Issue date:
5 Aug 2021